Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

+44 1300 500008

Rac1b-regulates the neuronal differentiation potential of human mesenchymal stem cells

International Conference & Exhibition on Cell Science & Stem Cell Research

29 Nov - 1 Dec 2011 Philadelphia Airport Marriott, USA

Kevin M. Curtis

Scientific Tracks Abstracts: J Cell Sci Ther

Abstract :

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive degeneration of motor neurons which leads to defi nitive muscular paralysis and fi nally to respiratory failure. We have previously shown that NSC are able to delay motor neuron degeneration aft er injection into the spinal cord of EAE multiple sclerosis mice model, to boost endogenous remyelination in the corpus callosum of focally demyelinated rats and to dampen microgliosis and astrogliosis into the ischemic brain of adult. Th ese results together with studies from other labs showing the effi cacy of neural precursors to delay ALS progression when transplanted into the spinal cord of ALS rodents have promoteD NSC transplantation as a therapeutic strategy. Moreover, cell therapy is reaching the stage of clinical application, with the fi rst few clinical trials already underway in some post traumatic, post-ischemic or neurodegenerative disorders. A standardized, clinical grade source of normal human CNS cells (hNSCs), combining the plasticity of foetal tissue with extensive proliferative capacity and functional stability would be of paramount importance in this fi eld. We established continuous and stable hNSC lines from the foetal CNS and showed their ability to integrate in the spinal cord of ALS animal model aft er transplantation. We are currently investigating some of the NSC-mediated therapeutic eff ects, such as trophic support to host cells and immunomodulation of the infl ammatory environment. It has to be emphasized that hNSC lines were grown according rules of Good Manufacturing Practices (GMP) in medium containing EGF and b-FGF according to the neurosphere assay paradigm and they have been recently approved by the Italian Agency of Pharmacology (AIFA) for clinical trial phase I on ALS patients.

Biography :

Lidia De Filippis is a senior Post-doc researcher by University Milan Bicocca, collaborator of Prof. Angelo Vescovi. She works on human neural stem cell-mediated therapy of neurodegenerative diseases and is currently involved in translational and pre-clinical research studies on Amyotrophic Lateral Sclerosis and Lysosomal Storage Diseases